CDK6 and urinary bladder carcinoma: In conclusion, our study demonstrated that IGF2BP3 regulated the cell cycle and cisplatin sensitivity in bladder cancer by enhancing CDK6 mRNA stability in an m6A-dependent manner, which maybe providing a new treatment strategy for bladder cancer patients, especially those with cisplatin resistance (Figure 9).